Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
FENCFennec Pharma(FENC) Newsfilter·2024-05-14 18:03

~ Achieved First Quarter 2024 Total Net Revenues of 25.4Million,Including25.4 Million, Including 18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement with Norgine to Commercialize PEDMARQSI™ in Europe, Australia, and New Zealand ~ ~ Amended PEDMARK Permanent J-code 07901 Became Effective April 1, 2024 ~ ~ Company Has Approximately $51 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RE ...